News - Page 167 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Post published:July 1, 2021
Post category:Press Release

Read more about the article Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

Harvard Law School’s Petrie-Flom Center Launches Research Initiative on Psychedelics and the Law

Post published:June 30, 2021
Post category:Analysis News

Read more about the article Psyched Wellness Announces Matthew Singh Joins Team as CPG and Branding Consultant

Psyched Wellness Announces Matthew Singh Joins Team as CPG and Branding Consultant

Post published:June 30, 2021
Post category:Press Release

Read more about the article Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana

Post published:June 30, 2021
Post category:Press Release

Read more about the article COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”

Post published:June 30, 2021
Post category:Press Release

Read more about the article Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Post published:June 29, 2021
Post category:Press Release

Read more about the article Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board

Post published:June 28, 2021
Post category:Press Release

Read more about the article COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression

Post published:June 28, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications

Awakn Life Sciences Files Patent Applications In U.S. For AWKN001 And AWKN002, Two Next- Generation New Chemical Entities [NCEs] To Treat A Broad Range Of Addiction Indications

Post published:June 28, 2021
Post category:Press Release

Read more about the article MindMed Included in FTSE Russell 3000® Index

MindMed Included in FTSE Russell 3000® Index

Post published:June 28, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.